Here are the eight companies currently being accelerated by Texas Medical Center Innovation. Photo courtesy of TMC

The Texas Medical Center Innovation has named its new cohort of health tech companies it's currently accelerating.

This first batch of companies for 2024 was selected from last fall's TMC Bootcamp. Eight of the 10 startups from the bootcamp have moved on to the Accelerator for HealthTech.

"Hailing from diverse corners of the globe—from the tech corridors of Texas and California to Ireland and Australia—these companies converge with a shared mission—to move healthcare forward," Devin Dunn, head of the Accelerator for Health Tech, writes in a TMC blog post. "Through personalized mentorship and guidance, these eight companies are able to navigate complex challenges and refine their strategies, while leveraging the expertise of Texas Medical Center ecosystem to validate their innovations and drive real-world impact."

The selected companies include:

  • AcorAI, from Stockholm, Sweden, which is developing a first-of-its-kind, hand-held, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.
  • AirSeal, based in St. Louis, Missouri, which has developed a novel serum-based biomarker technology – circulating fatty acid synthase (cFAS) – that can diagnose cardiovascular and peripheral artery disease with high accuracy in both women and men.
  • Foxo, headquartered in Brisbane, Australia, serves as an interoperable tool designed to enhance clinical collaboration across the healthcare ecosystem. It enables secure, two-way communication with features such as video, voice, screen share, file sharing, and real-time messaging.
  • San Francisco-based Knowtex, an artificial intelligence-powered software writes medical documentation for you and assigns correct codes to ensure proper reimbursement.
  • NeuroBell, from Cork, Ireland, which is working on a novel medical device providing portable EEG monitoring with real-time and automated neonatal seizure alerts at the bedside.
  • Perth, Australia-based OncoRes Medical that's developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure.
  • From right here in Houston, Steradian Technologies, which has created RUMI, the first noninvasive, fully portable infectious disease diagnostic that costs the price of a latte. It uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30 seconds.
  • TYBR, also based in Houston, created a flowable extracellular matrix hydrogel, crafted to safeguard healing tendons and ligaments from scarring and adhesions. The company originated from the TMCi’s Biodesign fellowship and now has entered into the Accelerator for HealthTech to sharpen its regulatory strategy, particularly in anticipation of FDA conversations.

Applications for the next Accelerator for HealthTech will open in May of this year.

Meet the latest global health tech startups to get an invite to Houston from TMC Innovation. Photo via tmc.edu

TMC names latest cohort of health tech startups for upcoming bootcamp

headed to Houston

The Texas Medical Center's innovation arm has again invited a set of health tech startups to mix and mingle with potential partners, investors, and customers in hopes to score a place in the HealthTech Accelerator.

For the 17th time, the TMC Innovation Factory is hosting its HealthTech Accelerator — starting first with announcing its bootcamp cohort, a process that includes bringing all 10 companies to Houston for valuable networking. A selection of the bootcamp will be invited into the full accelerator that will run into next spring.

The 10 selected companies with solutions from heart failure to chronic respiratory disease and more, according to TMC, include:

  • Acorai, from Stockholm, Sweden, which is developing a first-of-its-kind, hand-held, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for more than 64 million patients worldwide.
  • Singapore-based Aevice Health, a connected care platform powered by the world’s smallest smart wearable stethoscope to support chronic respiratory disease patients through their continuum of care.
  • AirSeal, based in St. Louis, Missouri, which has developed a novel serum-based biomarker technology – circulating fatty acid synthase (cFAS) – that can diagnose cardiovascular and peripheral artery disease with high accuracy in both women and men.
  • Candlelit Care, a Charlotte, North Carolina-based point-of-care digital platform focused on the prevention of perinatal mental and anxiety disorders (PMADs) among Black women and birthing parents.
  • San Francisco-based Knowtex, an artificial intelligence-powered software writes medical documentation for you and assigns correct codes to ensure proper reimbursement.
  • NeuroBell, from Cork, Ireland, which is working on a novel medical device providing portable EEG monitoring with real-time and automated neonatal seizure alerts at the bedside.
  • Perth, Australia-based OncoRes Medical that's developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure.
  • From right here in Houston, Steradian Technologies, which has created RUMI, the first noninvasive, fully portable infectious disease diagnostic that costs the price of a latte. It uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30 seconds.
  • Foxo, headquartered in Brisbane, Australia, serves as an interoperable tool designed to enhance clinical collaboration across the healthcare ecosystem. It enables secure, two-way communication with features such as video, voice, screen share, file sharing, and real-time messaging.
  • Thrive Health’s, from Vancouver, Canada, is a platform is a low-code framework for designing and delivering patient engagement solutions. Create tools that enable partners to close healthcare gaps quickly, strengthen care relationships, and improve patient experience and outcomes.

TMC Innovation's last bootcamp cohort was announced in May. The organization also recently named 16 digital health and medical device startups from the United Kingdom to a new accelerator formed in partnership with Innovate UK.

Earlier this fall, TMC formed a strategic partnership, or BioBridge, with the Netherlands.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Aegis Aerospace appoints Houston space leader as new president

moving up

Houston-based Aegis Aerospace's current chief strategy officer, Matt Ondler, will take on the additional role of president on Jan. 1. Ondler will succeed Bill Hollister, who is retiring.

“Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers,” Stephanie Murphy, CEO of Aegis Aerospace, said in a news release.

Hollister guided Aegis Aerospace through expansion and innovation in his three years as president, and will continue to serve in the role of chief technology officer (CTO) for six months and focus on the company's technical and intellectual property frameworks.

"Bill has played an instrumental role in shaping the success and growth of our company, and his contributions leave an indelible mark on both our culture and our achievements," Murphy said in a news release.

Ondler has a background in space hardware development and strategic leadership in government and commercial sectors. Ondler founded subsea robots and software company Houston Mechatronics, Inc., now known as Nauticus Robotics, and also served as president, CTO and CSO during a five-year tenure at Axiom Space. He held various roles in his 25 years at NASA and was also named to the Texas Aerospace Research and Space Economy Consortium Executive Committee last year.

"I am confident that with Matt at the helm as president and Bill supporting us as CTO, we will continue to build on our strong foundation and further elevate our impact in the space industry," Murphy said in a news release. "Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers."

Rice University launches new center to study roots of Alzheimer’s and Parkinson’s

neuro research

Rice University launched its new Amyloid Mechanism and Disease Center last month, which aims to uncover the molecular origins of Alzheimer’s, Parkinson’s and other amyloid-related diseases.

The center will bring together Rice faculty in chemistry, biophysics, cell biology and biochemistry to study how protein aggregates called amyloids form, spread and harm brain cells. It will serve as the neuroscience branch of the Rice Brain Institute, which was also recently established.

The team will work to ultimately increase its understanding of amyloid processes and will collaborate with the Texas Medical Center to turn lab discoveries into real progress for patients. It will hold its launch event on Jan. 21, 2026, and hopes to eventually be a launchpad for future external research funding.

The new hub will be led by Pernilla Wittung-Stafshed, a Rice biophysicist and the Charles W. Duncan Jr.-Welch Chair in Chemistry.

“To make a real difference, we have to go all the way and find a cure,” Wittung-Stafshede said in a news release. “At Rice, with the Amyloid Mechanism and Disease Center as a catalyst, we have the people and ideas to open new doors toward solutions.”

Wittung-Stafshede, who was recruited to Rice through a Cancer Prevention and Research Institute of Texas grant this summer, has led pioneering work on how metal-binding proteins impact neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Her most recent study, published in Advanced Science, suggests a new way of understanding how amyloids may harm cells and consume the brain’s energy molecule, ATP.

According to Alzheimer’s Disease International, neurodegenerative disease cases could reach around 78 million by 2030 and 139 million by 2050. Wittung-Stafshede’s father died of dementia several years ago.

“This is close to my heart,” Wittung-Stafshede added in the news release. “Neurodegenerative diseases such as dementia, Alzheimer’s and Parkinson’s are on the rise as people live longer, and age is the largest risk factor. It affects everyone.”

This Houston airport saw sharp passenger decline in 2025, study shows

Travel Talk

A new global airport travel study has revealed passenger traffic at Houston's William P. Hobby Airport (HOU) sharply decreased from 2024 to 2025.

The analysis from travel magazine LocalsInsider examined recently released data from the Bureau of Transportation Statistics (BTS), the U.S. International Trade Association, and a nationwide survey to determine the following American traveler habits: The most popular U.S. and international destinations, emerging hotspots, and destinations on the decline. The study covered passenger travel trends from January through July 2025.

In the report's ranking of the 40 U.S. airports with the sharpest declines in passenger traffic, HOU ranked 13th on the list.

About 4.26 million arrivals were reported at HOU from January through July 2024, compared to about 3.96 million during the same seven-month period in 2025. According to the data, that's a significant 7.1 percent drop in passenger traffic year-over-year, or a loss of 300,974 passengers.

"As travelers chase new hotspots, some destinations are seeing reduced passenger traffic whether due to rising costs, shifting airline schedules, or evolving traveler preferences, some destinations are seeing a decrease in visitors," the report's author wrote.

It appears most major Texas airports had drops in passenger traffic from 2024 to 2025. Dallas Love Field Airport (DAL) saw the worst in the state, with a dramatic 7.4 percent dip in arrivals. DAL also ranked 11th on the list of U.S. airports with the steepest declines in passenger traffic.

More than 5.13 million arrivals were reported at DAL from January through July 2024, compared to over 4.75 million during the same seven-month period in 2025.

This is how passenger traffic has fallen at other major Texas airports from 2024 to 2025:

Austin-Bergstrom International Airport (AUS):

  • 6,107,597 – Passenger arrivals from January to July 2024
  • 5,828,396 – Passenger arrivals from January to July 2025
  • -4.6 percent – Year-over-year passenger change
Dallas/Fort Worth International Airport (DFW):
  • 23,830,017 – Passenger arrivals from January to July 2024
  • 23,251,302 – Passenger arrivals from January to July 2025
  • -2.4 percent – Year-over-year passenger change

San Antonio International Airport (SAT):

  • 2,937,870 – Passenger arrivals from January to July 2024
  • 2,836,774 – Passenger arrivals from January to July 2025
  • -3.4 percent – Year-over-year passenger change
El Paso International Airport (ELP):
  • 1,094,431 – Passenger arrivals from January to July 2024
  • 1,076,845 – Passenger arrivals from January to July 2025
  • -1.6 percent – Year-over-year passenger change
---

This story originally appeared on CultureMap.com.